Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M4KN
|
||||
Former ID |
DNC013128
|
||||
Drug Name |
10S-hydroxylobelane
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H29NO
|
||||
Canonical SMILES |
CN1C(CCCC1CC(C2=CC=CC=C2)O)CCC3=CC=CC=C3
|
||||
InChI |
1S/C22H29NO/c1-23-20(16-15-18-9-4-2-5-10-18)13-8-14-21(23)17-22(24)19-11-6-3-7-12-19/h2-7,9-12,20-22,24H,8,13-17H2,1H3/t20-,21+,22+/m1/s1
|
||||
InChIKey |
MUSFCRGEWKAWEE-FSSWDIPSSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Sodium-dependent serotonin transporter | Target Info | Inhibitor | [1] | |
Sodium-dependent dopamine transporter | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Serotonergic synapsehsa04728:Dopaminergic synapse | ||||
Parkinson's disease | |||||
Cocaine addiction | |||||
Amphetamine addiction | |||||
Alcoholism | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
5HT2 type receptor mediated signaling pathway | |||||
5HT3 type receptor mediated signaling pathway | |||||
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis | |||||
Parkinson disease | |||||
Dopamine receptor mediated signaling pathway | |||||
Pathway Interaction Database | Alpha-synuclein signaling | ||||
Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
WikiPathways | Monoamine Transport | ||||
SIDS Susceptibility Pathways | |||||
NRF2 pathway | |||||
Synaptic Vesicle Pathway | |||||
Serotonin Transporter ActivityWP727:Monoamine Transport | |||||
Dopaminergic Neurogenesis | |||||
Parkinsons Disease Pathway | |||||
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
Neurotransmitter Clearance In The Synaptic Cleft | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. Epub 2006 Aug 14.Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.